Skin Sensitization Test (Modified Draize-95 Test)
1 other identifier
interventional
245
1 country
1
Brief Summary
Skin Sensitization Test (Modified Draize-95 Test) to Support a Low Dermatitis Potential Claim for a Blue Non Sterile Powder Free Nitrile Examination Gloves. This study is a RIPT (Repeat Insult Patch Test) to evaluate whether residual chemical additives at the level that may induce Type IV allergy in the nonsensitized general user population are present in a finished Blue Non Sterile Powder Free Nitrile Examination Glove.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2018
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 2, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 8, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 8, 2018
CompletedFirst Submitted
Initial submission to the registry
March 18, 2019
CompletedFirst Posted
Study publicly available on registry
March 22, 2019
CompletedMarch 22, 2019
March 1, 2019
2 months
March 18, 2019
March 21, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Irritation scored by Erythemal Scoring Scale
Basic Score and Description: 0 - No visible reaction. 0.5 - Doubtful or negligible erythema reaction. 1.0 - Mild or just perceptible macular erythema reaction in a speckled/follicular, patchy or confluent pattern (slight pinking). 2.0 - Moderate erythema reaction in a confluent pattern (definite redness). 3.0 - Strong or brisk erythema reaction that may spread beyond the test site. If a subject develops a positive reaction (a score value of 1.5) to the test material or shows signs of irritation after patch applications, further patching on those individuals are stopped. In order to qualify for the claim of a reduced sensitization potential, all 200 individuals completing the study should exhibit a score value of no more than 1.5 based on the scoring criteria.
8 weeks
Study Arms (1)
Device and Control
EXPERIMENTALBlue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact. Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml Negative control: Blank patch Dose: Not applicable
Interventions
Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
Eligibility Criteria
You may qualify if:
- Subjects must be aged 18 to 65 years, inclusive;
- Subjects who have not participated in other voluntary testing for at least 30 days;
- Subjects must execute an Informed Consent Form that includes a HIPAA statement; and
- Subjects must be capable of understanding and following directions.
- Female subjects must produce a negative urine pregnancy test prior to the initiation and also at the completion of the trial.
You may not qualify if:
- Subjects who are in ill health, as determined by the PI;
- Subjects who are taking medication, other than birth control, which could influence the purpose, integrity or outcome of the trial;
- Subjects who have used topical or systemic corticosteroids, anti-inflammatories, antihistamines or antibiotics within 2 weeks prior to trial initiation or during their participation on this trial;
- Female subjects who are pregnant as evidenced by a urine pregnancy test, planning to become pregnant or lactating during the trial;
- Subjects who have a history of adverse reactions to cosmetics, OTC drugs, or other personal care products;
- Subjects who introduce the use of any new cosmetic, toiletry or personal care products during the trial;
- Subjects with any visible skin disease that might be confused with skin reactions caused by the test material;
- Subjects with any knowledge or indication of existing Type IV allergy (delayed hypersensitivity) to natural rubber chemical additives;
- Subjects with any indication of existing Type I allergy (immediate hypersensitivity) to natural rubber proteins;
- Subjects with a history of frequent irritation; or
- Subjects who have received endogenous or exogenous immunosuppressive treatment (or prolonged exposure to sun).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Central Medicare Sdn. Bhd.lead
- Consumer Product Testing Company, Inc.collaborator
Study Sites (1)
Consumer Product Testing Company, Inc.
Fairfield, New Jersey, 07004, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Caswell, Ph.D., CCRA, CCRC
Consumer Product Testing Company, Inc.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 18, 2019
First Posted
March 22, 2019
Study Start
April 2, 2018
Primary Completion
June 8, 2018
Study Completion
June 8, 2018
Last Updated
March 22, 2019
Record last verified: 2019-03
Data Sharing
- IPD Sharing
- Will not share